• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Assessment of Median and Mean Survival Time in Cancer Clinical Trials.

作者信息

Das Ananya, Lin Timothy A, Lin Christine, Meirson Tomer, McCaw Zachary R, Tian Lu, Ludmir Ethan B

机构信息

The University of Texas MD Anderson Cancer Center, Houston.

Johns Hopkins University School of Medicine, Baltimore, Maryland.

出版信息

JAMA Netw Open. 2023 Apr 3;6(4):e236498. doi: 10.1001/jamanetworkopen.2023.6498.

DOI:10.1001/jamanetworkopen.2023.6498
PMID:37010873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10071342/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fcb/10071342/6d041b019c4c/jamanetwopen-e236498-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fcb/10071342/6d041b019c4c/jamanetwopen-e236498-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fcb/10071342/6d041b019c4c/jamanetwopen-e236498-g001.jpg

相似文献

1
Assessment of Median and Mean Survival Time in Cancer Clinical Trials.癌症临床试验中中位生存期和平均生存期的评估。
JAMA Netw Open. 2023 Apr 3;6(4):e236498. doi: 10.1001/jamanetworkopen.2023.6498.
2
Clinical Trial Evidence Supporting US Food and Drug Administration Approval of Novel Cancer Therapies Between 2000 and 2016.2000 年至 2016 年间支持美国食品和药物管理局批准新型癌症疗法的临床试验证据。
JAMA Netw Open. 2020 Nov 2;3(11):e2024406. doi: 10.1001/jamanetworkopen.2020.24406.
3
Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer.免疫检查点抑制剂治疗癌症的临床试验中通过受限平均生存时间衡量的治疗效果。
Ann Oncol. 2018 May 1;29(5):1320-1324. doi: 10.1093/annonc/mdy075.
4
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?中位生存时间与平均生存时间：哪项指标对患者、医生和决策者最适用？
Oncologist. 2019 Nov;24(11):1469-1478. doi: 10.1634/theoncologist.2019-0175. Epub 2019 Jul 18.
5
A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.促红细胞生成素α、促红细胞生成素β和达比加群酯治疗癌症相关性贫血（尤其是癌症治疗所致贫血）的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. doi: 10.3310/hta11130.
6
How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials.我还有多长时间？对转移性乳腺癌一线化疗初治患者的典型、最佳和最差情况进行估算：近期随机试验的系统评价。
J Clin Oncol. 2011 Feb 1;29(4):456-63. doi: 10.1200/JCO.2010.30.2174. Epub 2010 Dec 28.
7
Up-to-date long-term survival of cancer patients: an evaluation of period analysis on Swedish Cancer Registry data.癌症患者的最新长期生存率：基于瑞典癌症登记数据的时期分析评估
Eur J Cancer. 2004 Jun;40(9):1361-72. doi: 10.1016/j.ejca.2004.02.004.
8
Assessment of Outcomes Associated With the Use of Newly Approved Oncology Drugs in Medicare Beneficiaries.评估在医疗保险受益人群中使用新批准的肿瘤药物相关的结局。
JAMA Netw Open. 2021 Feb 1;4(2):e210030. doi: 10.1001/jamanetworkopen.2021.0030.
9
Predicting Mean Survival Time from Reported Median Survival Time for Cancer Patients.根据癌症患者报告的中位生存时间预测平均生存时间。
Med Decis Making. 2017 May;37(4):391-402. doi: 10.1177/0272989X16655341. Epub 2016 Jul 10.
10
An expanded portfolio of survival metrics for assessing anticancer agents.用于评估抗癌药物的生存指标扩展组合。
Am J Manag Care. 2017 Jan;23(1):54-61.

引用本文的文献

1
Descriptive statistics for cardiothoracic surgeons: part 2 - the foundation of data interpretation.心胸外科医生的描述性统计：第2部分 - 数据解读的基础。
Indian J Thorac Cardiovasc Surg. 2025 Jan;41(1):89-110. doi: 10.1007/s12055-024-01855-x. Epub 2024 Nov 8.
2
Gastroesophageal reflux disease and risk of incident lung cancer: A large prospective cohort study in UK Biobank.胃食管反流病与肺癌发病风险的前瞻性队列研究：英国生物库研究。
PLoS One. 2024 Nov 11;19(11):e0311758. doi: 10.1371/journal.pone.0311758. eCollection 2024.
3
Proportional Hazards Violations in Phase III Cancer Clinical Trials: A Potential Source of Trial Misinterpretation.

本文引用的文献

1
Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations.肿瘤学临床试验中时间相关终点设计与分析的陷阱及建议
JNCI Cancer Spectr. 2022 Jan 5;6(1). doi: 10.1093/jncics/pkac007.
2
Transparency in reporting of phase 3 cancer clinical trial results.III期癌症临床试验结果报告的透明度。
Acta Oncol. 2021 Feb;60(2):191-194. doi: 10.1080/0284186X.2020.1856410. Epub 2020 Dec 13.
3
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
三期癌症临床试验中比例风险违反：潜在的试验误解来源。
Clin Cancer Res. 2024 Oct 15;30(20):4791-4799. doi: 10.1158/1078-0432.CCR-24-0566.
4
Lost in the plot: missing visual elements in Kaplan-Meier plots of phase III oncology trials.迷失在情节中：三期肿瘤学临床试验中 Kaplan-Meier 图中缺失的视觉元素。
Oncologist. 2024 Jul 5;29(7):547-550. doi: 10.1093/oncolo/oyae067.
5
Challenges in analyzing clinical trials testing Bruton tyrosine-kinase-inhibitora in chronic lymphocytic leukaemia.分析慢性淋巴细胞白血病中布鲁顿酪氨酸激酶抑制剂临床试验的挑战。
Leukemia. 2024 Jul;38(7):1469-1473. doi: 10.1038/s41375-024-02294-8. Epub 2024 Jun 1.
6
Assessing the effect of metastasis-directed therapy in oligometastatic disease using the restricted mean survival time.使用限制平均生存时间评估寡转移疾病中转移导向治疗的效果。
Br J Cancer. 2024 Jun;130(12):1929-1935. doi: 10.1038/s41416-024-02700-z. Epub 2024 May 6.
7
Increase in the Life Expectancy of Patients with Cancer in the United States.美国癌症患者预期寿命的增长
Cancer Epidemiol Biomarkers Prev. 2024 Feb 6;33(2):196-205. doi: 10.1158/1055-9965.EPI-23-1006.
8
Challenges, Complexities, and Considerations in the Design and Interpretation of Late-Phase Oncology Trials.晚期肿瘤学试验设计和解读中的挑战、复杂性和注意事项。
Semin Radiat Oncol. 2023 Oct;33(4):429-437. doi: 10.1016/j.semradonc.2023.06.007.
中位生存时间与平均生存时间：哪项指标对患者、医生和决策者最适用？
Oncologist. 2019 Nov;24(11):1469-1478. doi: 10.1634/theoncologist.2019-0175. Epub 2019 Jul 18.
4
Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.使用受限平均生存时间替代风险比来解释癌症临床试验结果的可解释性。
JAMA Oncol. 2017 Dec 1;3(12):1692-1696. doi: 10.1001/jamaoncol.2017.2797.
5
Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis.超越风险比：在生存分析中量化组间差异。
J Clin Oncol. 2014 Aug 1;32(22):2380-5. doi: 10.1200/JCO.2014.55.2208. Epub 2014 Jun 30.
6
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.增强型生存数据分析：从已发表的 Kaplan-Meier 生存曲线中重建数据。
BMC Med Res Methodol. 2012 Feb 1;12:9. doi: 10.1186/1471-2288-12-9.